Open AccessA prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers
Author(s) -
Zelen Charles M,
Orgill Dennis P,
Serena Thomas,
Galiano Robert,
Carter Marissa J,
DiDomenico Lawrence A,
Keller Jennifer,
Kaufman Jarrod,
Li William W
Publication year - 2017
Publication title -
international wound journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.867
H-Index - 63
eISSN - 1742-481X
pISSN - 1742-4801
DOI - 10.1111/iwj.12600
Subject(s) - medicine , adverse effect , diabetic foot , reticular dermis , surgery , wound healing , randomized controlled trial , incidence (geometry) , diabetes mellitus , clinical trial , dermis , physics , optics , anatomy , endocrinology
Abstract Acellular dermal matrices can successfully heal wounds. This study's goal was to compare clinical outcomes of a novel, open‐structure human reticular acellular dermis matrix ( HR‐ADM ) to facilitate wound closure in non‐healing diabetic foot ulcers ( DFUs ) versus DFUs treated with standard of care ( SOC ). Following a 2‐week screening period in which DFUs were treated with offloading and moist wound care, patients were randomised to either SOC alone or HR‐ADM plus SOC applied weekly for up to 12 weeks. At 6 weeks, the primary outcome time, 65% of the HR‐ADM ‐treated DFUs healed (13/20) compared with 5% (1/20) of DFUs that received SOC alone. At 12 weeks, the proportions of DFUs healed were 80% and 20%, respectively. Mean time to heal within 12 weeks was 40 days for the HR‐ADM group compared with 77 days for the SOC group. There was no incidence of increased adverse or serious adverse events between groups or any adverse events related to the graft. Mean and median graft costs to closure per healed wound in the HR‐ADM group were $1475 and $963, respectively. Weekly application of HR‐ADM is an effective intervention for promoting closure of non‐healing DFUs .